Table 3

Blood glucose Measure	Dapagliflozin monotherapy in 389 treatment-naïve patients in a 12-week study						Dapagliflozin as an add-on to metformin in 546 patients inadequately controlled by metformin alone in a 24-week study				Dapagliflozin combination therapy in 71 patients inadequately controlled by insulin plus OADs in a 12-week study
	2.5mg	5mg	10mg	20mg	50mg	Placebo	2.5 mg	5mg	10mg	Placebo	10mg	20mg	Placebo
Mean change from baseline in FPG (mg/dl)	-16	-19	-21	-24	-31	-6	-17.8	-21.5	-23.5	-6.0	-2.4	-9.6	17.8
Change from baseline in PPG	-9382^a	-8478^a	-10149^a	-7053^a	-10,093^a	-3182^a					-34.3^b	-41.9^b	18.7^a
Mean absolute change from baseline in HbA1c (%)	-0.71	-0.72	-0.85	-0.55	-0.90	-0.18	-0.67	-0.70	-0.84	-0.30	-0.61	-0.69	0.09

AUC: Area Under the Curve; FPG: Fasting Plasma Glucose; HbA1c: Hemoglobin A1c; OAD: Oral Antidiabetic Drug; PPG: Postprandial Plasma Glucose. ^aMean change in AUC ((mg/dL)*min), ^bPlasma glucose levels measured after 120 min during a 75 g oral glucose tolerance test [31].

Table 3: Effect of dapagliflozin on blood glucose parameters.